v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 26, 2026
Segment Reporting [Abstract]  
Segment Results Detailed segment data for the three and six-month periods ended June 26, 2026 and June 27, 2025 is as follows ($ in millions):
BiotechnologyLife SciencesDiagnosticsTotal Reportable Segments
Other(a)
Total
For the Three-Month Period Ended June 26, 2026:
Sales$1,920 $1,879 $2,466 $6,265 $— $6,265 
Less:
Depreciation(40)(48)(107)(195)(1)(196)
Amortization of intangible assets(231)(151)(81)(463)— (463)
Other segment items(c)
(1,093)(1,436)(1,862)(4,391)(88)(4,479)
Operating profit$556 $244 $416 $1,216 $(89)$1,127 
For the Three-Month Period Ended June 27, 2025:
Sales$1,850 $1,777 $2,309 $5,936 $— $5,936 
Less:
Depreciation(38)(45)(100)(183)(2)(185)
Amortization of intangible assets(228)(150)(48)(426)— (426)
Impairments(b)
— (432)— (432)— (432)
Other segment items(c)
(1,053)(1,389)(1,607)(4,049)(84)(4,133)
Operating profit (loss)$531 $(239)$554 $846 $(86)$760 
BiotechnologyLife SciencesDiagnosticsTotal Reportable Segments
Other(a)
Total
For the Six-Month Period Ended June 26, 2026:
Sales$3,717 $3,616 $4,883 $12,216 $— $12,216 
Less:
Depreciation(80)(96)(209)(385)(4)(389)
Amortization of intangible assets(465)(303)(129)(897)— (897)
Other segment items(c)
(2,082)(2,748)(3,455)(8,285)(174)(8,459)
Operating profit$1,090 $469 $1,090 $2,649 $(178)$2,471 
For the Six-Month Period Ended June 27, 2025:
Sales$3,462 $3,457 $4,758 $11,677 $— $11,677 
Less:
Depreciation(72)(90)(200)(362)(4)(366)
Amortization of intangible assets(441)(299)(96)(836)— (836)
Impairments(b)
(15)(432)— (447)— (447)
Other segment items(c)
(1,962)(2,674)(3,190)(7,826)(168)(7,994)
Operating profit (loss)$972 $(38)$1,272 $2,206 $(172)$2,034 
(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.
(b) For information on the impairments, refer to Note 8.
(c) Other segment items for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses.
The following table presents identifiable assets as of June 26, 2026 and December 31, 2025 ($ in millions):
June 26, 2026December 31, 2025
Biotechnology$36,009 $37,337 
Life Sciences22,593 23,112 
Diagnostics25,731 14,748 
Other8,034 8,267 
Total$92,367 $83,464 
The following table presents capital expenditures, gross for the three and six-month periods ended June 26, 2026 and June 27, 2025 ($ in millions):
Three-Month Period EndedSix-Month Period Ended
June 26, 2026June 27, 2025June 26, 2026June 27, 2025
Biotechnology$66 $80 $130 $161 
Life Sciences38 41 65 89 
Diagnostics164 125 308 240 
Other1 2 3 3 
Total$269 $248 $506 $493